-
Mashup Score: 4
Kim N. Chi, MD, FRCPC, discusses results from the MAGNITUDE trial, including those on survival and patient-reported outcomes in patients with BRCA-positive metastatic castration-resistant prostate cancer receiving niraparib plus abiraterone acetate and prednisone.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1MRI-Based Risk Calculators May Improve Patient Selection for Prostate Biopsy - Renal and Urology News - 1 month(s) ago
All models underpredicted the risk of clinically significant prostate cancer to some degree, supporting the use and future inclusion of advanced biomarkers.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2Localized or Advanced Prostate Cancer Short- or Longer-Term Relugolix Plus Radiotherapy - The ASCO Post - 1 month(s) ago
In an analysis reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that treatment with relugolix was associated with rapid achievement of sustained castration in patients with localized or advanced prostate cancer who were also receiving radiotherapy. The analysis included patients from a phase II trial of relugolix vs degarelix and a subset of patients from the phase III HERO trial of relugolix vs leuprolide acetate, including 65 patients who received radiotherapy and short-term (24
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Multi-dose phase of 64Cu/67Cu-SAR-bisPSMA study begins in mCRPC - 1 month(s) ago
Among all patients treated in the study to date, 60% demonstrated a PSA reduction of greater than 35%, and 27% demonstrated a PSA reduction of greater than 80%.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Black Men Face Highest Incidence of Prostate Cancer in the UK - Renal and Urology News - 2 month(s) ago
However, for advanced-stage prostate cancer, incidence similar to that of White men
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2
In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Dr Childs on Treatment With Olaparib Plus Abiraterone in mCRPC - 2 month(s) ago
Dan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Relugolix Plus Radiotherapy in Localized or Advanced Prostate Cancer - 2 month(s) ago
This study examines 2 randomized clinical trials to assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Dr Childs on Treatment With Olaparib Plus Abiraterone in mCRPC - 2 month(s) ago
Dan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 32Relugolix Plus Radiotherapy in Localized or Advanced Prostate Cancer - 2 month(s) ago
This study examines 2 randomized clinical trials to assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
Kim N. Chi, MD, FRCPC, discusses data from the MAGNITUDE trial in patients with BRCA-positive metastatic castration-resistant prostate cancer receiving niraparib + abiraterone acetate and prednisone. #PCSM | @BCCancer https://t.co/nTD4X6TI5v